86677-62-5

Basic information

• Product Name: 24-fluoro-1,25-dihydroxycholecalciferol
• Synonyms: 24-fluoro-1,25-dihydroxycholecalciferol
• CAS NO: 86677-62-5
• Molecular Formula: C₂₇H₄₃FO₃
• Molecular Weight: 434.63
• Mol File: 86677-62-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 579.1°C at 760 mmHg
• Flash Point: 304°C
• Appearance: /
• Density: 1.09g/cm³
• Vapor Pressure: 8.05E-16mmHg at 25°C
• Refractive Index: 1.538
• CAS DataBase Reference: 24-fluoro-1,25-dihydroxycholecalciferol(CAS DataBase Reference)
• NIST Chemistry Reference: 24-fluoro-1,25-dihydroxycholecalciferol(86677-62-5)
• EPA Substance Registry System: 24-fluoro-1,25-dihydroxycholecalciferol(86677-62-5)

Safety Data

• Hazardous Substances Data: 86677-62-5(Hazardous Substances Data)

Usage

Type

Synthetic derivative of vitamin D

Chemical Modification

Contains a fluorine atom at the 24th position of its molecular structure

Purpose

Mimics the biological activity of natural vitamin D

Function

Regulates calcium and phosphate levels in the body

Therapeutic Potential

Investigated for treating disorders related to vitamin D deficiency, such as osteoporosis and bone mineral disorders

Additional Potential

Being researched for potential anti-inflammatory and immune-modulatory properties

Research Status

Ongoing studies to fully understand its benefits and risks

InChI:InChI=1/C27H43FO3/c1-17(8-13-25(28)26(3,4)31)22-11-12-23-19(7-6-14-27(22,23)5)9-10-20-15-21(29)16-24(30)18(20)2/h9-10,17,21-25,29-31H,2,6-8,11-16H2,1,3-5H3/b19-9+,20-10-/t17-,21+,22-,23+,24-,25-,27-/m1/s1

Upstream product

• 86677-75-0 3(R)-fluoro-4-methyl-1,4-pentanediol 
• 112138-99-5 <1R-<1β(1R^*,3R^*),3aα,4β,7aβ>>-α-<4-(1-ethoxyethoxy)-3-fluoro-4-methylpentyl>octahydro-4-<(tetrahydro-2H-pyran-2-yl)oxy>-7a-methyl-1H-indene-1-ethanol 4-methylbenzenesulfonate 
• 112138-97-3 <1R-<1β(1R^*,3R^*),3aα,4β,7aβ>>-α-<4-(1-ethoxyethoxy)-3-fluoro-4-methylpentyl>octahydro-4-<(tetrahydro-2H-pyran-2-yl)oxy>-7a-methyl-1H-indene-1-acetic acid ethyl ester 
• 112138-98-4 <1R-<1β(1R^*,3R^*),3aα,4β,7aβ>>-α-<4-(1-ethoxyethoxy)-3-fluoro-4-methylpentyl>octahydro-4-<(tetrahydro-2H-pyran-2-yl)oxy>-7a-methyl-1H-indene-1-ethanol 
• 112139-00-1 <1R-<1β(1R^*,3R^*),3aα,4β,7aβ>>-1-<5-(1-ethoxyethoxy)-4-fluoro-1,5-dimethylhexyl>octahydro-4-<(tetrahydro-2H-pyran-2-yl)oxy>-7a-methyl-1H-indene 
• 112138-95-1 <3aR-(3aα,4β,7aβ)>--7a-methyl-1H-inden-1-ylidene>acetic acid ethyl ester 
• 107900-39-0 (R)-4-(1-ethoxyethoxy)-3-fluoro-4-methyl-1-pentanol 4-methylbenzenesulfonate 
• 112139-03-4 <1R-<1β(1R^*,4R^*),3aα,7aβ>>-1-<4-fluoro-1,5-dimethyl-5-<(trimethylsilyl)oxy>hexyl>octahydro-7α-methyl-4H-inden-4-one 
• 112138-96-2 <1R-(1β,3aα,4β,7aβ)>-octahydro-4-<(tetrahydro-2H-pyran-2-yl)oxy>-7a-methyl-1H-indene-1-acetic acid ethyl ester 
• 112151-59-4 <1R-<1β(1R^*,4R^*),3aα,7aβ>>-1-(4-fluoro-5-hydroxy-1,5-dimethylhexyl)octahydro-7α-methyl-4H-inden-4-one 
• 112138-94-0 <3aR-(3aα,4β,7aβ)>-octahydro-4-<(tetrahydro-2H-pyran-2-yl)oxy>-7a-methyl-1H-inden-1-one 
• 112139-02-3 <1R-<1β(1R^*,4R^*),3aα,4β,7aβ>>-β-fluorooctahydro-4-hydroxy-α,α,ε,7a-tetramethyl-1H-indene-1-pentanol 
• 107900-37-8 (R)-4-(1-ethoxyethoxy)-3-fluoro-4-methyl-1-pentanol acetate 
• 86677-76-1 3(R)-fluoro-4-methyl-1,4-pentanediol 1-acetate 

Relevant articles and documents

Triply convergent synthesis of 1α,25-dihydroxy-24(R)-fluorocholecalciferol

-

Synthesis of 1α,25-dihydroxy-24R-fluorocholecalciferol and 1α,25-dihydroxy-24S-fluorocholecalciferol

1α,25-Dihydroxy-24R-fluorocholecalciferol and 1α,25-dihydroxy-24S-fluorocholecalciferol, analogs of 1α,25-dihydroxy-cholecalciferol which is physiologically the most active metabolite of vitamin D3, are synthesized in a multistep process from the known substance 1α,3β-dihydroxyandrost-5-en-17-one. The new analogs are characterized by the ability to increase intestinal calcium transport, increase serum calcium and phosphate concentrations and to increase the deposition of these minerals in bones. These compounds will find a ready application as substitutes for natural 1α,25-dihydroxycholecalciferol in the treatment of disease states characterized by metabolic calcium and phosphate deficiencies. Exemplary of such disease states are the following: osteosclerosis, anticonvulsant treatment, osteopenia, fibrogenesis-imperfecta ossium, secondary hyperparathyrodism, hypoparathyroidism, hyperparathyroidism, cirrhosis, obstructive jaundice, drug induced metabolism, medullary carcinoma, chronic renal disease, hypophosphatemic VDRR, vitamin D-dependent rickets, sarcoidosis, glucocorticoid antagonism, malabsorption syndrome, steatorrhea, tropical sprue, idiopathic hypercalcemia and milk fever.